GLPG vs. TGTX, BBIO, AXSM, TLX, BPMC, GRFS, NUVL, KRYS, VRNA, and CYTK
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include TG Therapeutics (TGTX), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Grifols (GRFS), Nuvalent (NUVL), Krystal Biotech (KRYS), Verona Pharma (VRNA), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.
Galapagos vs.
TG Therapeutics (NASDAQ:TGTX) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends.
Galapagos has lower revenue, but higher earnings than TG Therapeutics.
TG Therapeutics presently has a consensus target price of $40.67, indicating a potential upside of 1.16%. Galapagos has a consensus target price of $26.75, indicating a potential upside of 4.90%. Given Galapagos' higher possible upside, analysts plainly believe Galapagos is more favorable than TG Therapeutics.
In the previous week, TG Therapeutics had 7 more articles in the media than Galapagos. MarketBeat recorded 11 mentions for TG Therapeutics and 4 mentions for Galapagos. Galapagos' average media sentiment score of 1.77 beat TG Therapeutics' score of 1.37 indicating that Galapagos is being referred to more favorably in the news media.
TG Therapeutics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.
TG Therapeutics received 193 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 63.84% of users gave Galapagos an outperform vote.
58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Galapagos shares are held by institutional investors. 10.5% of TG Therapeutics shares are held by insiders. Comparatively, 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Galapagos has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. Galapagos' return on equity of 0.00% beat TG Therapeutics' return on equity.
Summary
TG Therapeutics beats Galapagos on 10 of the 16 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
This page (NASDAQ:GLPG) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy GLPG Stock Free GLPG Stock Alerts